Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis ...

New study finds that elevated S100A8/A9 levels in blood may be associated with cognitive impairment in adults with #lupus.

A new study identifies eight domains of active systemic #lupus erythematosus for defining meaningful treatment response in ...

In this randomized trial, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a ...

The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

Investigators assessed the frequency of lupus flares in patients with kidney failure undergoing dialysis or with a kidney transplant.

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

Riya began to get "off" feelings at the age of 22. Her symptoms were subtle: body aches, periodic low-grade fevers, fatigue ...

The following is a summary of “2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and ...

Some patients with lupus who possess specific antibodies are at a higher risk of thrombotic events such as a blood clot, stroke or heart attack, a new study led by Johns Hopkins ...

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery ...